Abstract:Abstract Combining multiple types of genomic, transcriptional, proteomic, and epigenetic datasets has the potential to reveal biological mechanisms across multiple scales, and may lead to more accurate models for clinical decision support. Developing efficient models that can derive clinical outcomes from high-dimensional data remains problematical; challenges include the integration of multiple types of omics data, inclusion of biological background knowledge, and developing machine learning models that are able to deal with this high dimensionality while having only few samples from which to derive a model. We developed DeepMOCCA, a framework for multi-omics cancer analysis. We combine different types of omics data using biological relations between genes, transcripts, and proteins, combine the multi-omics data with background knowledge in the form of protein–protein interaction networks, and use graph convolution neural networks to exploit this combination of multi-omics data and background knowledge. DeepMOCCA predicts survival time for individual patient samples for 33 cancer types and outperforms most existing survival prediction methods. Moreover, DeepMOCCA includes a graph attention mechanism which prioritizes driver genes and prognostic markers in a patient-specific manner; the attention mechanism can be used to identify drivers and prognostic markers within cohorts and individual patients. Author summary Linking the features of tumors to a prognosis for the patient is a critical part of managing cancer. Many methods have been applied to this problem but we still lack accurate prognostic markers for many cancers. We now have more information than ever before on the state of the cancer genome, the epigenetic changes in tumors, and gene expression at both RNA and protein levels. Here, we address the question of how this data can be used to predict cancer survival and discover which tumor genes make the greatest contribution to the prognosis in individual tumor samples. We have developed a computational model, DeepMOCCA, that uses artificial neural networks underpinned by a large graph constructed from background knowledge concerning the functional interactions between genes and their products. We show that with our method, DeepMOCCA can predict cancer survival time based entirely on features of the tumor at a cellular and molecular level. The method confirms many existing genes that affect survival but for some cancers suggests new genes, either not implicated in survival before or not known to be important in that particular cancer. The ability to predict the important features in individual tumors provided by our method raises the possibility of personalized therapy based on the gene or network dominating the prognosis for that patient.

Tissue-specific identification of multi-omics features for pan-cancer drug response prediction

An Innovative Multi-Omics Model Integrating Latent Alignment and Attention Mechanism for Drug Response Prediction

The prediction of drug sensitivity by multi-omics fusion reveals the heterogeneity of drug response in pan-cancer

Advancing drug-response prediction using multi-modal and -omics machine learning integration (MOMLIN): a case study on breast cancer clinical data

Drug Response Modeling across Cancers: Proteomics vs. Transcriptomics

Improving Drug Sensitivity Prediction and Inference by Multitask Learning

Model ensembling as a tool to form interpretable multi-omic predictors of cancer pharmacosensitivity

Anti-cancer Drug Synergy Prediction in Understudied Tissues using Transfer Learning

Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer

Structured penalized regression for drug sensitivity prediction

A multi-view multi-omics model for cancer drug response prediction

Prediction of drug sensitivity based on multi-omics data using deep learning and similarity network fusion approaches

Multi-task deep latent spaces for cancer survival and treatment response prediction

Deep learning and multi-omics approach to predict drug responses in cancer

MMFSyn: A Multimodal Deep Learning Model for Predicting Anticancer Synergistic Drug Combination Effect

Circumventing Drug Resistance in Gastric Cancer: A Spatial Multi-omics Exploration of Chemo and Immuno-Therapeutic Response Dynamics

Multi-task deep latent spaces for cancer survival and drug sensitivity prediction

Drug combination prediction for cancer treatment using disease-specific drug response profiles and single-cell transcriptional signatures

Pancancer survival prediction using a deep learning architecture with multimodal representation and integration

Cancer immunotherapy response prediction from multi-modal clinical and image data using semi-supervised deep learning

DeepMOCCA: A pan-cancer prognostic model identifies personalized prognostic markers through graph attention and multi-omics data integration